Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in EAEU has been experiencing significant growth in recent years.
Customer preferences: Patients suffering from rheumatoid arthritis and other rheumatic diseases are the primary customers of Anti-Rheumatic Drugs. They prefer drugs that provide quick relief from pain and inflammation, with minimal side effects. Additionally, patients prefer drugs that are affordable and easily accessible.
Trends in the market: The Anti-Rheumatic Drugs market in EAEU has been growing due to the increasing prevalence of rheumatic diseases in the region. The market has also been driven by the introduction of new drugs that are more effective and have fewer side effects. Moreover, the market has been witnessing a shift towards biologic drugs, which are more expensive but provide better results.In terms of market share, non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used Anti-Rheumatic Drugs in EAEU. However, biologic drugs are expected to gain more market share in the coming years due to their effectiveness in treating rheumatic diseases.
Local special circumstances: EAEU member countries have different healthcare systems and policies, which affect the availability and affordability of Anti-Rheumatic Drugs. For instance, in some countries, these drugs are not covered by health insurance, making them unaffordable for many patients. Moreover, the availability of these drugs varies across the region, with some countries having better access to new and innovative drugs than others.
Underlying macroeconomic factors: The growing middle class in EAEU member countries has increased the demand for healthcare services, including Anti-Rheumatic Drugs. Additionally, the aging population in the region has contributed to the increasing prevalence of rheumatic diseases. The economic growth in the region has also led to an increase in healthcare spending, which has further boosted the Anti-Rheumatic Drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
